CUE — Cue Biopharma Share News
0.000.00%
Last trade - 00:00- $102.72m
- $86.34m
- $27.47m
Cue Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Cue Biopharma Appoints Patrick Verheyen To Its Board Of Directors
Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cue Biopharma Reports Fourth Quarter Results
Cue Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Cue Biopharma Enters Into A Strategic Collaboration With Ono Pharmaceutical For Cue-401
Brief: Cue Biopharma Announces Chief Medical Officer Transition
Brief: Cue Biopharma Inc Files Prospectus Relates To Resale From Time To Time Of Up To 18.4 Million Shares Of Common Stock By Selling Stockholders - Filing
Cue Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cue Biopharma Reports Third Quarter 2022 Financial Results
Cue Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Cue Biopharma Presents New Positive Data From Ongoing Phase 1 Trial Of Cue-101 In Combination With Keytruda R
U.S. STOCKS ON THE MOVE-Illumina, energy firms, Cue Biopharma
Cue Biopharma gains on FDA's 'fast track' tag for cancer drug candidate
U.S. RESEARCH ROUNDUP- Cooper Companies, Intuit, Nordson Corp
Brief: Cue Biopharma Doses First Patient In Phase 1 Study Of Cue-102 For Wilms' Tumor 1 (Wt1) - Expressing Cancers
Brief: Cue Biopharma Reports Second Quarter 2022 Financial Results
Brief: Cue Biopharma To Present At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting
Brief: Cue Biopharma Receives FDA Acceptance Of IND Application For CUE-102 In WT1